Opus Genetics Secures FDA Alignment on Phase 3 Trial for LCA5 Gene Therapy — Opus Genetics, Inc.

Event summary

Opus Genetics reached FDA alignment on Phase 3 trial design for OPGx-LCA5 in LCA5-associated inherited retinal disease.
FDA allows BLA submission based on 6-month efficacy data, with 12-month durability data provided during review.
Phase 3 study expects to enroll eight participants, with seven already enrolled and dosing set to begin in 4Q 2026.
Primary endpoint is a mean improvement of at least 7 decibels (dB) in retinal sensitivity.

The big picture

Opus Genetics' FDA alignment on the Phase 3 trial design for OPGx-LCA5 marks a critical milestone in the development of gene therapies for ultra-rare inherited retinal diseases. The streamlined regulatory pathway, allowing BLA submission based on shorter-term efficacy data, reflects the FDA's increasing flexibility in approving treatments for severe, untreatable conditions. This development positions Opus Genetics to potentially become a key player in the gene therapy space, particularly for rare pediatric diseases.

What we're watching

Regulatory Pathway: How the FDA's acceptance of 6-month efficacy data will impact the BLA submission timeline and review process.
Clinical Execution: Whether Opus Genetics can maintain the pace of enrollment and dosing initiation in the Phase 3 trial as planned for 4Q 2026.
Strategic Asset: The potential impact of a Priority Review Voucher on Opus Genetics' strategic positioning and valuation.